Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Kalundborg, Denmark.

Last week, the Danish pharmaceutical company announced that it is now investing in expanding its manufacturing facilities in Denmark. The plan is to expand and create more space for the production of active pharmaceutical ingredients (API).

“The significant investment announced today confirms the importance of utilising our existing sites, including in Denmark, as cornerstones for not only the growth we see but also to expand as fast as possible by utilising all the infrastructure, knowledge and competences we already have”, says Henrik Wulff, Head of Product Supply, Quality & IT for Novo Nordisk, in a press release.

The construction is expected to be completed between 2025 and 2029 and will measure 170,000 square meters. Novo Nordisk expects the investment to create 800 new job opportunities in the new facilities once it is fully equipped.

The factory in Kalundborg manufactures Novo Nordisk’s treatments for, among other things, obesity and diabetes.

Artikeln är en del av vårt tema om News in English.

Kommentera en artikel
Utvalda artiklar


Sänd till en kollega